Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways.
The metabolic syndrome is a worldwide epidemic, setting the stage for type 2 diabetes and its microvascular complications, and acceleration of macrovascular disease. Insulin resistance, hyperglycemia, dyslipidemia, hypertension, thrombotic disorders and adiposity define the metabolic syndrome and contribute to endothelial dysfunction and, subsequently, to accelerated atherosclerosis. Angiotensin II contributes to the development and progression of cardiovascular and renal endpoints and, as such, angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors demonstrate a protective effect. Ligands for the peroxisome proliferator-activated receptor gamma (PPAR gamma), appear to impact favourably on atherosclerosis through both direct and indirect mechanisms. In humans, these ligands improve endothelial function, attenuate albuminuria and hypertension, and potentially prevent conversion of prediabetes to type 2 diabetes. Statins also have proven benefit in decreasing overall cardiovascular and stroke mortality and morbidity. The combination of angiotensin II blockade, statin therapy and PPAR gamma activation might emerge as an important global therapeutic strategy in the metabolic syndrome and diabetes. Further studies are needed to determine whether they have synergistic effects to protect the vasculature.
Caglayan
Evren
E
Klinik III für Innere Medizin, Klinikum der Universität zu Köln, Joseph-Stelzmann-Str. 9, D-50924 Köln, Germany.
Blaschke
Florian
F
Takata
Yasunori
Y
Hsueh
Willa A
WA
D000818:Animals; D002318:Cardiovascular Diseases / Q000378:metabolism* / Q000517:prevention & control; D006801:Humans; D024821:Metabolic Syndrome / Q000378:metabolism* / Q000517:prevention & control; D009765:Obesity / Q000378:metabolism / Q000517:prevention & control